hims & hers fda warning letter compounded semaglutide 2025 and Novo Nordisk Warn of GLP-1 Telehealth Compounding Take Down – What's Next? U.S. FDA sends drug advertising

From click to research-ready compound, the process is fast, transparent, and fully supported

Retatrutide is the agonist of GLP-1 receptor, GIP receptor, and glucagon (GCG) receptor, which can reduce body weight and improve blood glucose by subcutaneous injection once a week(Rosenstock et al 2023)

DV supervised the writing

Lillys oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

This will reduce the risk of infection

Understanding these differences helps set realistic expectations and avoid disappointment or confusion